VRCAVerrica Pharmaceuticals Inc.

$56M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+47.7% YoY

Gross Profit

$5M63.8% margin

Operating Income

-$66M-871.3% margin

Net Income

-$77M-1012.1% margin

EPS (Diluted)

$-14.78

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$61M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$54M

Total Liabilities

$64M

Stockholders' Equity

-$10M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$5M	+47.7%
Gross Profit	$5M	$4M	+10.2%
Operating Income	-$66M	-$66M	-0.2%
Net Income	-$77M	-$67M	-14.3%

VRCA FY 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena